Etoposide (VP-16)

Epidemiology

  • Indications
    • Non-small Cell Lung Cancer
    • Small Cell Lung Cancer

Pharmacology

  • Podophyllotoxin agent
  • Topoisomerase-II inhibitor

Clinical Presentations

  • Acute Lung Injury-ARDS (see Acute Lung Injury-ARDS)
    • Epidemiology
      • Only a few reported cases
      • Synergistic Toxicity with Methotrexate (see Methotrexate): etoposide increases intracellular methotrexate levels
    • Diagnosis
      • OLB: alveolar edema, diffuse alveolar damage, atypical type II pneumocytes
    • Clinical: onset shortly after first round of etoposide or after prolonged treatment
    • Treatment/Prognosis: withdrawal of drug + corticosteroids -> variable response

References

  • xxx